6 completed, 4 unknown, 3 recruiting, 1 terminated. 15 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 6, Unknown 4, Recruiting 3, Terminated 1, Withdrawn 1 |
| Phase 1 | 4 | Unknown 3, Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Malignant Ascites: new trials by email Literature Review of Malignant Ascites trials Research Report on Malignant Ascites
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy liposomal irinotecan monotherapy, Liposomal Irinotecan + rmhTNF-NC, Liposomal Irinotecan + Bevacizumab - Malignant Ascites | Phase 1 / Phase 2 | Recruiting | Dong sheng Zhang | 48 | 2025-11-28 | 2026-02-09 |
| The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites serplulimab, Bevacizumab, rmhTNF-NC - Malignant Ascites | Phase 2 | Recruiting | Sun Yat-sen University | 60 | 2023-12-14 | 2024-05-30 |
| PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites Serplulimab, Molgramostim, Hypofractionated radiotherapy/Sterotactic body radiotherapy - Malignant Ascites | Phase 1 / Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 40 | 2022-09-01 | 2022-08-15 |
| Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody M701, paracentesis - Malignant Ascites | Phase 2 | Completed | Wuhan YZY Biopharma Co., Ltd. | 115 | 2021-11-24 | 2026-06-17 |
| A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites BSG-001 - Malignant Pleural Effusion, Malignant Ascites | Phase 1 / Phase 2 | Unknown | BioSyngen Pte Ltd | 58 | 2019-01-01 | 2018-11-08 |
| Clinical Study of Autologous Erythrocytes Derived MPs Packaging MTX Peritoneal Perfusion to Treat Malignant Ascites Erythrocytes derived MPs containing MTX, convention drugs - Malignant Ascites | Phase 1 / Phase 2 | Unknown | Hui ting Xu，MD | 18 | 2017-05-01 | 2017-07-26 |
| A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites Apatinib - Malignant Ascites, Apatinib | Phase 2 | Recruiting | The First Affiliated Hospital of Bengbu Medical University | 120 | 2017-01-01 | 2026-09-03 |
| Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer metformin hydrochloride, placebo, Chemotherapy - Brenner Tumor, Malignant Ascites | Phase 2 | Completed | University of Chicago | 111 | 2015-02-25 | 2026-03-27 |
| Safety and Effectiveness Study of Tumor Cell-derived Microparticles to Treat Malignant Ascites and Pleural Effusion Drug-packaging microparticles - Malignant Pleural Effusion,, Malignant Ascites | Phase 2 | Unknown | Huazhong University of Science and Technology | 30 | 2013-05-01 | 2013-10-01 |
| Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites Endostar, Cisplatin - Malignant Pleural Effusion, Malignant Ascites | Phase 2 | Completed | Jiangsu Simcere Pharmaceutical Co., Ltd. | 336 | 2011-03-01 | 2014-08-01 |
| Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural Effusion immediate cediranib, Start cediranib after 28 days Best Supportive Care - Malignant Ascites, Malignant Pleural Effusion | Phase 2 | Terminated | Radboud University Medical Center | 12 | 2010-04-01 | 2013-07-15 |
| Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers Bevacizumab, Placebo - Malignant Ascites, Gastrointestinal Cancers | Phase 2 | Completed | AIO-Studien-gGmbH | 53 | 2010-02-01 | 2015-04-13 |
| A Study of Bevacizumab to Prevent Malignant Ascites Bevacizumab - Malignant Ascites | Phase 2 | Withdrawn | Baylor College of Medicine | 2009-07-01 | 2015-06-03 | |
| Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites catumaxomab - Malignant Ascites | Phase 2 | Completed | Neovii Biotech | 32 | 2006-06-01 | 2018-10-17 |
| Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group Catumaxomab (Removab), paracentesis - EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast), Malignant Ascites | Phase 2 / Phase 3 | Completed | Neovii Biotech | 258 | 2004-09-01 | 2009-02-05 |
Pleural Effusion, Malignant (5) · Ascites (2) · Carcinoma, Ovarian Epithelial (2) · Fallopian Tube Neoplasms (2) · Brenner Tumor (1) · Carcinoma (1) · Gastrointestinal Neoplasms (1) · Neoplasms, Glandular and Epithelial (1) · Ovarian Neoplasms (1) · Peritoneal Neoplasms (1) · Pleural Effusion (1)
Neoplasms (7) · Neoplasms by Site (7) · Pleural Diseases (5) · Pleural Neoplasms (5) · Respiratory Tract Diseases (5) · Respiratory Tract Neoplasms (5) · Thoracic Neoplasms (5) · Pleural Effusion (4) · Adnexal Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Fallopian Tube Diseases (2) · Female Urogenital Diseases (2)
Bevacizumab (4) · Paracentesis (2) · catumaxomab (2) · Cisplatin (1) · Drug Therapy (1) · Immune Checkpoint Inhibitors (1) · Metformin (1) · apatinib (1) · cediranib (1) · endostar protein (1) · irinotecan sucrosofate (1) · molgramostim (1) · recombinant human tumor necrosis factor-binding protein-1 (1) · regramostim (1)
Neovii Biotech (2) · AIO-Studien-gGmbH (1) · Baylor College of Medicine (1) · BioSyngen Pte Ltd (1) · Dong sheng Zhang (1) · Huazhong University of Science and Technology (1) · Hui ting Xu，MD (1) · Jiangsu Simcere Pharmaceutical Co., Ltd. (1) · Radboud University Medical Center (1) · Second Affiliated Hospital of Soochow University (1) · Sun Yat-sen University (1) · The First Affiliated Hospital of Bengbu Medical University (1) · University of Chicago (1) · Wuhan YZY Biopharma Co., Ltd. (1)
China (7) · United States (3) · Australia (1) · Germany (1) · Netherlands (1)
Bo Huang, Ph.D (1) · Jianming Xu, MD (1) · Jonathan Berek, MD MMSc (1) · Karin Jordan, Dr. med. (1) · Lietao Li, MD (1) · Martha P Mims, MD, PhD (1) · Seiko Yamada (1) · Shukui Qin, MD (1)